- The trend backdrop is active with a 33-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
IPCALAB
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Ipca Laboratories Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
1,736 INR
-0.2%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 9.9% above the Trend Line and sits at 70.5% of its 52-week range. The latest completed week returned -0.2%, after a -2.6% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 44/100. Near-term considerations: volume confirmation is below normal.
Setup score
63
out of 100
Latest Close
1,736 INR
7 Aug 2026
1W Return
-0.2%
latest completed week
4W Return
-2.6%
short-term follow-through
12W Return
8.1%
quarterly tape
Trend Breadth
65.4%
34 of 52 weeks active
Volume Ratio
0.9x
vs 13-week average
- 5 reversal markers appear in the recent smart-money tape.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-0.2%
Latest completed week; four-week move -2.6%.
Indicator stack
81/72
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
44/100
18 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 9.9% above the Trend Line and sits at 70.5% of its 52-week range. The latest completed week returned -0.2%, after a -2.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.8612-week average 0.81
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.86Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers55 reversal markers
No recent accumulation markers. 5 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -2.6% over four weeks, 8.1% over 12 weeks, and 25.2% over one year. The current trend has remained active for 33 consecutive weeks.
Performance by holding period
Active trend streak33 weeks
Active weeks in one year34
Trend breadth65.4%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.10Latest activity-pressure read.
Pressure change32.7%Four-week change in activity pressure.
Leadership16.24Latest relative-leadership reading.
RS change-30.6%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 94%
Model confidence 88%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength65/100Blend of value, momentum, and quality. Underlying universe rank 36; rank 1 is best.
Value24/100Relative valuation strength. Underlying universe rank 77; rank 1 is best.
Quality93/100Profitability and accounting quality. Underlying universe rank 8; rank 1 is best.
Momentum83/100Medium-term price momentum. Underlying universe rank 18; rank 1 is best.
Growth71/100Revenue and earnings growth. Underlying universe rank 30; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework39/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 38.6x Price divided by trailing earnings.
- Price / sales
- 4.6x Market value relative to trailing revenue.
- EV / EBITDA
- 22.2x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 1.1% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 70.7% Gross profit retained from each unit of revenue.
- Operating margin
- 16.2% Operating profit retained from revenue.
- Free-cash-flow margin
- 5.0% Free cash flow generated from revenue.
- Return on invested capital
- 13.9% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 8.0% Latest one-year revenue growth.
- EPS growth
- 54.7% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -10.9% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 9/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.3% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.3% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.2x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment44/100
Weighted news tone is neutral across 18 relevant articles.
4 positive · 13 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-10.4%Distance below the 52-week high.
13-week volatility4.7%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher14 of 2612 weeks finished lower.
Best week+9.5%Week of 3 Jul.
Worst week-7.3%Week of 24 Jul.
Latest week-0.2%Week of 7 Aug.
Shape of recent returns
Strong gains7
Modest gains7
Flat weeks0
Modest losses9
Sharp losses3
Recent vol4.7%13-week weekly-return volatility.
Base vol4.4%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew3.9% / -2.9%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank68 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank56 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape66/100
Trend, activity pressure, participation, and risk combine to a 66/100 tape read.
Indicator analysis81/100Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.
Activity pressure 0.86; 5 reversal markers Factors66/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 39 SVQF39/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 959.5 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment44/100Weighted news tone is neutral across 18 relevant articles.
Ipca Laboratories Shares Fall 2% to Rs 1,701 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 1,736 INR | -0.2% | 1,580 INR | 1,364 INR | 1.10 | 16.24 | 904.3K | On |
| 31 Jul 2026 | 1,740 INR | -1.0% | 1,575 INR | 1,359 INR | 1.30 | 17.91 | 770.0K | On |
| 24 Jul 2026 | 1,757 INR | -7.3% | 1,564 INR | 1,354 INR | 1.43 | 22.62 | 1.2M | On |
| 17 Jul 2026 | 1,894 INR | 6.3% | 1,553 INR | 1,348 INR | 1.24 | 29.69 | 1.8M | On |
| 10 Jul 2026 | 1,782 INR | 0.5% | 1,537 INR | 1,341 INR | 0.83 | 23.39 | 943.5K | On |
| 3 Jul 2026 | 1,773 INR | 9.5% | 1,527 INR | 1,334 INR | 0.52 | 23.08 | 571.4K | On |
| 26 Jun 2026 | 1,618 INR | 2.0% | 1,516 INR | 1,328 INR | 0.37 | 14.00 | 0 | On |
| 19 Jun 2026 | 1,586 INR | 0.2% | 1,511 INR | 1,322 INR | 0.30 | 12.47 | 262.4K | On |
| 12 Jun 2026 | 1,583 INR | -3.6% | 1,506 INR | 1,317 INR | 0.56 | 14.59 | 132.0K | On |
| 5 Jun 2026 | 1,642 INR | 7.7% | 1,503 INR | 1,311 INR | 0.84 | 20.62 | 242.3K | On |
| 29 May 2026 | 1,524 INR | -4.8% | 1,492 INR | 1,305 INR | 0.72 | 11.70 | 1.3M | On |
| 22 May 2026 | 1,602 INR | -0.2% | 1,483 INR | 1,300 INR | 0.70 | 16.82 | 1.5M | On |
| 15 May 2026 | 1,605 INR | 3.4% | 1,472 INR | 1,294 INR | 0.50 | 17.76 | 3.0M | On |
| 8 May 2026 | 1,553 INR | 1.4% | 1,462 INR | 1,288 INR | -0.06 | 11.86 | 897.5K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.